TAVR in Bicuspid Has the Same Results in Surgery at Hospital Level

Courtesy of Dr. Carlos Fava.

Bicuspid aortic stenosis patients (bicuspid AS) represent a small group and have not been included in the larger transcatheter aortic valve replacement (TAVR) studies, since they present different morphology and asymmetric calcification, which might come along with more paravalvular leak and less accurate positioning.

El reemplazo transcatéter en válvulas bicúspides suma evidencia pero continúan los desafíos

Between 2012 and 2016, 475,315 patients undergoing TAVR or surgical aortic valve replacement (SAVR) were included in the National Inpatient Sample database. 31.895 of these patients presented bicuspid aortic stenosis and 1055 (10.4%) received TAVR; the rest received SAVR.

Those undergoing TAVR were older, more often were women, diabetic, hypertensive and more often presented cardiac failure, kidney function deterioration, stroke, peripheral vascular disease, and implantable cardioverter-defibrillator. Therefore, a propensity score match was carried out, leaving 975 patients in each group.


Read also: Revascularization in Spontaneous Coronary Artery Dissection Causing ST-Segment Elevation Myocardial Infarction


In-hospital mortality was 3.1% in both groups. In addition, there were no differences between the strategies as regards cardiorespiratory arrest, cardiogenic shock, kidney function deterioration, stroke and the need for ventricular assistance. However, TAVR was associated to lower acute myocardial infarction rate (1% vs. 3.1% p=0.002), bleeding (23.6% vs. 44.6% p<0.001), transfusion (7.2% vs. 27.2% p<0.001), vascular complications (0.5% vs. 2.6% p<0.001), in-hospital stay (4 days vs. 7 days p<0.01), lower need for discharge to nursing facility (14.4% vs. 17.9% p=0.04) and lower respiratory assistance.

On the other hand, TAVR was associated with higher complete heart block (14.9% vs. 6.2% p<0.001) and need for definite pacemaker (13.8 vs. 4.6% p<0.001).

On the other hand, there were no differences in TAVR between bicuspids and tricuspids.

Conclusion

The National Inpatient Sample database showed similar mortality in severe bicuspid aortic stenosis patients undergoing TAVR or SAVR. Besides, TAVR presented similar mortality vs. tricuspid valves. further research is needed to assess long term evolution of TAVR in bicuspid aortic stenosis.

Courtesy of Dr. Carlos Fava.

Temporal Trends and Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement for Bicuspid Aortic Valve Stenosis.

Reference: Ayman Elbadawi, et al. J Am Coll Cardiol Intv 2019;12:1811–22.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...